Oral Darolutamide presentation at ASCO on 31 May 2019
Impact of Darolutamide on Pain and Quality of Life in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) at ASCO taking place in Chicago.
At the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019, taking place May 31 to June 4 in Chicago, Illinois (USA) in an oral presentation, new data evaluating the impact of darolutamide on pain and quality of life outcomes in non-metastatic castration-resistant prostate cancer (nmCRPC) patients from the Phase III ARAMIS trial will be presented.
The U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for darolutamide for the treatment of nmCRPC in April 2019. Additionally, Bayer has filed for approval in the EU as well as Japan and is also in discussions with other health authorities regarding submissions. Darolutamide is being developed jointly by Orion and Bayer.
Oral presentation on Darolutamide
- Impact of Darolutamide (DARO) on Pain and Quality of Life (QoL) in Patients (Pts) with Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC)
- Oral presentation #5000, Session: Genitourinary (Prostate) Cancer
- Friday, May 31, 2:45 PM - 2:57 PM CDT, Room: Arie Crown Theater
Darolutamide is a non-steroidal androgen receptor (AR) antagonist with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. In preclinical studies, darolutamide demonstrated lower blood-brain barrier penetration compared to other currently available AR antagonists.2
In addition to the Phase III trial ARAMIS in men with nmCRPC, darolutamide is also being investigated in a Phase III study in metastatic hormone-sensitive prostate cancer (ARASENS). Information about these trials can be found at www.clinicaltrials.gov.
Darolutamide is not approved by the U.S. FDA, the European Medicines Agency or any other health authority.